

CHEM MED CHEM

CHEMISTRY ENABLING DRUG DISCOVERY



14/2017

Front Cover Picture:

Garrett C. Moraski, Marvin J. Miller et al.

Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds

WILEY-VCH

www.chemmedchem.org


A Journal of



G. C. Moraski,* R. Bristol, N. Seeger,
H. I. Boshoff, P. S.-Y. Tsang, M. J. Miller*



Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds



The front cover picture shows promising pentafluorosulfanyl (SF_5) anti-tuberculosis compounds 6-chloro-2-ethyl-*N*-(3-(pentafluoro- λ^6 -sulfaneyl)benzyl)imidazo[1,2-*a*]pyridine-3-carboxamide (**18**) and 2,6-dimethyl-*N*-(4-(pentafluoro- λ^6 -sulfaneyl)benzyl)imidazo[2,1-*b*]thiazole-5-carboxamide (**19**) ascending a mountain of in vitro assessments (including replicating, nonreplicating, and intracellular potency, toxicity, solubility, and ADME). These SF_5 -bearing compounds were also compared with similar CF_3 -bearing compounds 2,6-dimethyl-*N*-(4-(trifluoromethyl)benzyl)imidazo[1,2-*a*]pyridine-3-carboxamide (**1**) and 2,6-dimethyl-*N*-(4-(trifluoromethyl)benzyl)imidazo[2,1-*b*]thiazole-5-carboxamide (**5**). The overarching goal is to advance compounds within the next “mountains” of preclinical evaluation. Cover art created by Rebecca Rausch. More information can be found in the Full Paper by Garrett C. Moraski, Marvin J. Miller et al. (DOI: 10.1002/cmdc.201700170).